Loading…
← CockpitCompetitor Analysis › 0867.HK China Medical System Holdings Ltd.Open in the cockpit ↗

China Medical System Holdings Ltd.0867.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese specialty pharma that in-licenses drugs from global partners and markets them to Chinese hospitals.

≈ A Chinese drug-licensing/marketing specialistMomentum neutral 44
Mkt cap
$2.95B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$5.78M
20-day average traded
Fwd P/E
9.8×
forward earnings
ROIC−WACC
+0.6 pp
WACC 9.9%
Hurdle
-2 pp
Req g minus delivered
Next earnings
118 days
16 Mar 2027
Close · HKDHK$9.59
1D-2.0%
1W-7.8%
1M-7.7%
3M-18.1%
6M-15.2%
YTD-25.7%
1Y-30.5%
ATR %4.5%
52w lowhigh38.2% off high

What China Medical System does

Chinese specialty pharma that in-licenses drugs from global partners and markets them to Chinese hospitals.

Buys the rights to sell drugs in China from foreign and domestic developers, then markets them through its own sales force to hospitals and through distributors, keeping the margin between sales and what it pays for the rights. Growth comes from adding drugs, so the licensing pipeline matters as much as sales.

In one line: A Chinese drug-licensing/marketing specialist.

Products and services

  • Cardiovascular/urology drugs
  • Gastroenterology drugs
  • Dermatology & other specialty drugs

Customers

  • Hospitals and physicians in China

Where it sits in the supply chain

  • Pharmaceuticals
  • In-licensed drug marketing
  • Hospital sales network

What could go right

  • Expanding in-licensed drug portfolio

What could go wrong

  • Dependent on renewing/extending license agreements

Moat: narrow (distribution, regulatory licence). Established hospital sales force and regulatory relationships ease new in-licensed launches.

Headquarters: Shenzhen, China · Founded: 2000 · Employees: 6,415

Named competitors

China Medical System at a glance

Size China Medical System (0867.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $2.95B, the 336th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$9.59 on 18 Nov 2026.

Performance Over six months the shares fell 15.2%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 14.8% over the last twelve months (peer median +9.4%); the operating margin is 20.0% (peer median 11.3%).

Valuation It trades at 9.8× forward earnings against a peer median of 28.6× (cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -2 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.6 points above its cost of capital (9.9% WACC).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026Peer median 960867.HK 86
Six months, rebased to 100: China Medical System against the median of its 20 peers (local-currency closes).

China Medical System financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$9.74BHK$8.91BHK$8.10BHK$8.85BHK$10.6B
Revenue growth—+10%-9%-17%—
Gross profitHK$6.93BHK$6.37BHK$5.88BHK$6.75BHK$8.18B
EBITDAHK$2.26BHK$2.00BHK$2.07BHK$3.20BHK$4.40B
Net incomeHK$1.72BHK$1.61BHK$1.76BHK$2.65BHK$3.79B
Free cash flowHK$1.29BHK$1.14BHK$1.64BHK$3.06BHK$4.22B
Capital expenditureHK$886MHK$558MHK$494MHK$351MHK$610M
Total debtn/aHK$769MHK$916MHK$1.43BHK$2.04B

Quarterly statements and history in the cockpit →

China Medical System competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%NEULANDLAB002773VCEL6003802696ACADLEGN688266600535300558300199BIOA-B600518VKTX000739IDYAPPLPHARMA2096VRDN0867.HK6-month return →1-month return →
Up and to the right = strong over both horizons. China Medical System is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%0×50×100×150×NEULANDLAB002773VCEL6003802696ACADLEGN688266300558300199BIOA-B000739PPLPHARMA20960867.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Medical System is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%002773VCEL6003802696ACAD688266600535300558300199600511BIOA-B0007390867.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. China Medical System is the large dot.

China Medical System competitors and peer comparison

Head to head with its named competitors (0867.HK vs 1513.HK vs 2096.HK vs 2196.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
China Medical System 0867.HK$2.95B-15%+15%20%9.8×1.1%
Livzon Pharmaceutical 1513.HK$3.73B-9%-10%19%11.3×-7.0%
Simcere Pharmaceutical 2096.HK$3.42B-5%+27%18%13.5×-3.4%
Shanghai Fosun Pharmaceutical (Group) 2196.HK$7.74B-15%+10%6%9.0×19.9%

How China Medical System compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Medical System against its 20 peers (data as of 18 Nov 2026)
Measure0867.HKPeer medianRank in peer set
1-month return-7.7%+0.3%8th lowest of 21
6-month return-15.2%-6.6%6th lowest of 21
Distance from 52-week high-38.2%-29.6%8th lowest of 21
Revenue growth (TTM)+14.8%+9.4%10th highest of 20
Operating margin20.0%11.3%6th highest of 20
Forward P/E9.8×28.6×cheapest of 17
Growth the price implies (Req g, 7 yrs)1.1%9.2%6th least demanding of 14
Growth delivered (Del g)+2.7%+10.6%3rd lowest of 14
Hurdle (Req g minus delivered)-1.6 pp-10.2 pp6th most demanding of 14
ROIC minus cost of capital+0.6 pp+3.0 pp7th lowest of 17
EV / EBITDA7.8×27.6×cheapest of 8
Net debt / EBITDA-2.5×-0.8×3rd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a

Questions

Who are China Medical System's main competitors?
Named competitors: Livzon Pharmaceutical (1513.HK), Simcere Pharmaceutical (2096.HK), Fosun Pharma (2196.HK). The cockpit's measured peer set (industry) also includes Neuland Laboratories (NEULANDLAB.NS), Chengdu Kanghong Pharmaceutical (002773.SZ), Vericel (VCEL), Joincare Pharmaceutical Group Industry (600380.SS), Shanghai Henlius Biotech (2696.HK), ACADIA Pharmaceuticals (ACAD).
Is China Medical System expensive compared with its peers?
On forward p/e it trades at 9.8× against a peer median of 28.6×, cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -2 pp: the price already allows for a slowdown.
How has China Medical System stock performed?
Over six months to 18 Nov 2026 the shares returned -15.2% against -6.6% for the median peer; over one year -30.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.